<DOC>
	<DOC>NCT00326989</DOC>
	<brief_summary>Extracorporal shock wave therapy is performed prior to cell therapy for induction of therapeutic neovascularization and improvement of homing of bone marrow progenitor cells in patients with chronic ischemic heart disease following anterior myocardial infarction. Shock waves can induce growth factor expression in the ischemic myocardium and might augment homing of autologous bone marrow mononuclear cells which are injected intracoronary 24 h following shock wave therapy</brief_summary>
	<brief_title>Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium</brief_title>
	<detailed_description>Single center, Phase I-II Study (Safety, Feasibility and Efficacy) Double-blind, randomised trial (Cell therapy), single blind (Shockwave)</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients with chronic ischemic heart disease Patients with anterior myocardial infarction &gt; 3months EF &lt; 50% or NYHA IIIV Age 1880 Informed consent Ventricular thrombus Infarct &lt; 3 months. Active infection or fever Chronic inflammatory disease (e.g M. Crohn, Rheumatoid Arthritis) HIV Infection oder active Hepatitis Neoplastic disease w/o complete remission within 5 years Stroke &lt; 3months Creatinine &gt; 2 mg/dl Relevant Liver disease (GOT &gt; twice the upper limit). Anemia (Hemoglobin &lt;10 mg/dl) Thrombocytopenia &lt; 100.000/Âµl Allergies to Aspirin, Clopidogrel, Heparin History of bleeding disorder History of coagulopathy Gastrointestinal Bleeding &lt; 3 months Surgery or Trauma &lt; 2 months Pregnancy Mental Retardation Participation in other clinical study &lt; 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extracorporal shock wave therapy</keyword>
	<keyword>Cell therapy</keyword>
</DOC>